Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of Farxiga (dapagliflozin) versus other glucose-lowering medicines in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i).

Next Previous
Search
Trial Profile

A Study of Farxiga (dapagliflozin) versus other glucose-lowering medicines in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i).

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary) ; Canagliflozin; Empagliflozin; Ipragliflozin; Luseogliflozin; Tofogliflozin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms CVD-REAL 2

    • Most Recent Events

    • 01 Jun 2021 Results comparing the risk of HHF or death in T2D patients starting SGLT2inhibitors versus other glucose lowering drugs (OGLDs) according to baseline LVEF published in the Diabetes, Obesity and Metabolism
    • 19 Jun 2018 According to an AstraZeneca media release, data from this trial will be presented at the American Diabetes Association's (ADA) 78th Scientific Sessions 2018.
    • 19 Mar 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top